ArticleScience (New York, N.Y.)2019
Lactose drives
3 registry-linked trialsOpen access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 245 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
245citing papers in PubMed, 2 pooled it
24.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nutrition OUtReach In Systems of Healthcare
Remotely Monitored, Mobile Health-supported, High Intensity Interval Training Before Hematopoietic Stem Cell Transplantation (REMM-HIIT-HCT)
Comparative Effect of Proton Pump Inhibitors and Gastric Mucosal Protective Agents on Acute Graft-versus-Host Disease Post-Transplantation: A Prospective Randomized Controlled Trial
Who cites it
245 citing papers in PubMed, 2 syntheses or guidelines pooled it, 360 citations in OpenAlex.
- The characteristics of the gut microbiota in patients with Kawasaki disease: a systematic review.Frontiers in microbiology · 2025Pooled it
- The association of intestinal microbiota diversity and outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.Annals of hematology · 2023Pooled it
- Enteral versus parenteral nutrition in auto-HCT: a randomized controlled trial on clinical outcomes and gut microbiome dynamics.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study.Journal for immunotherapy of cancer · 2025Trial
- Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation.Blood advances · 2025Trial
- Trial
- Fecal microbiota transplantation to prevent acute graft-versus-host disease: pre-planned interim analysis of donor effect.Nature communications · 2025Trial
- Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Trial
- Mortality and microbial diversity after allogeneic hematopoietic stem cell transplantation: secondary analysis of a randomized nutritional intervention trial.Scientific reports · 2021Trial
- Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients.Nature communications · 2021Trial
- Review
- Longitudinal gut microbiome dynamics are associated with clinical outcome and toxicity during ibrutinib therapy.Gut microbes · 2026Article
- Overconsumption of fructose aggravates acute GVHD by inducing gut dysbiosis and promoting macrophage-mediated inflammatory response.Gut microbes · 2026Article
- The gut microbiome in graft-versus-host disease: mechanisms of immune modulation and therapeutic approaches.Gut microbes · 2026Review
- Longitudinal ecological disruption and metabolite associations of the gut microbiome during acute myeloid leukemia therapy.Microbiology spectrum · 2026Article
- Article
- Risk Factors and Outcomes of Vancomycin-ResistantOpen forum infectious diseases · 2026Article
- Article
185 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
53 authors at 10 institutions in 3 countries.
C K Stein-ThoeringerDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8020-6986
K B NicholsDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-0817-1667
A LazrakDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
M D DocampoDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8364-8432
A E SlingerlandDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4394-6862
J B SlingerlandDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
A G ClurmanAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
G ArmijoDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
A L C GomesDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3790-3724
Y ShonoDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-0459-1659
A StaffasDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8373-7312
M Burgos da SilvaDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8630-7211
S M DevlinEpidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
K A MarkeyDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7064-2362
D BajicDepartment of Internal Medicine II, Technical University of Munich, Munich, Germany.
R PinedoGnotobiotic Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2171-147X
A TsakmaklisDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
E R LittmannDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-8233-9256
A PastoreDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3621-4807
Y TaurInfectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6601-8284
S MonetteLaboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-2841-6887
M E ArcilaDiagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
A J PickardDonald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8376-1355
M MaloyAdult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
R J WrightDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5299-0024
L A AmorettiDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4625-5119
E FontanaDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
D PhamDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-0985-2109
M A JamalDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
D WeberInternal Medicine III, University Clinic Regensburg, Regensburg, Germany.
A D SungDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
D HashimotoDepartment of Hematology, Hokkaido University, Faculty of Medicine, Sapporo, Japan.ORCID 0000-0001-9489-9704
C ScheidDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
J B XavierComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3592-1689
J A MessinaDivision of Infectious Diseases, Department of Medicine, Duke University, Durham, NC, USA.ORCID 0000-0001-6411-198X
K RomeroOffice of Clinical Research, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-8131-2019
M LewDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-9183-569X
A BushDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-4495-3765
L BohannonDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-9197-3830
K HayasakaDivision of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan.
Y HasegawaDepartment of Hematology, Hokkaido University, Faculty of Medicine, Sapporo, Japan.ORCID 0000-0002-9925-2093
M J G T VehreschildDepartment I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
J R CrossDonald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
D M PonceWeill Cornell Medical College, New York, NY, USA.
M A PeralesWeill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-5910-4571
S A GiraltWeill Cornell Medical College, New York, NY, USA.ORCID 0000-0003-1944-5053
R R JenqDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5434-439X
T TeshimaDepartment of Hematology, Hokkaido University, Faculty of Medicine, Sapporo, Japan.ORCID 0000-0002-0941-271X
E HollerInternal Medicine III, University Clinic Regensburg, Regensburg, Germany.
N J ChaoDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0001-6725-7220
E G PamerDepartment of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6755-9904
J U Peled *Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. peledj@mskcc.org vandenbm@mskcc.org.ORCID 0000-0002-4029-7625
M R M van den Brink *Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. peledj@mskcc.org vandenbm@mskcc.org.ORCID 0000-0003-0696-4401
Memorial Sloan Kettering Cancer Center · USDuke Medical Center · USHokkaido University · JPThe University of Texas MD Anderson Cancer Center · USDuke University · USUniversity Hospital Regensburg · DEUniversity of Cologne · DEGoethe University Frankfurt · DEHokkaido University Hospital · JPTechnical University of Munich · DE
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MT LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PAMER, ERIC G. · 1985 to 2023
$59.0MResource Core 3 - Metabolomics CoreP30AG028716 · NIA · DUKE UNIVERSITY · PI Virginia B Kraus · 2006 to 2026
$24.6MThymic and Peripheral Aspects of T Cell Aging and RejuvenationP01AG052359 · NIA · UNIVERSITY OF ARIZONA · PI JANKO Z. NIKOLICH · 2017 to 2026
$23.5MSystems Biology of Microbiome-mediated Resilience to Antibiotic-resistant PathogensU01AI124275 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI PAMER, ERIC G., XAVIER, JOAO · 2016 to 2020
$8.9MProtecting colonic mucus to mitigate acute intestinal graft-versus-host diseaseR01HL124112 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI JENQ, ROBERT · 2015 to 2024
$6.8MThe role of intestinal microbiota in graft-versus-host diseaseR01CA228308 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Philip L Lorenzi, Marcel R M van den Brink · 2018 to 2026
$5.2MThe role of autophagy gene Atg16L1 in allogeneic hematopoietic stem cell transplantation - Resubmission - 1R01HL123340 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CADWELL, KEN HASHIGIWA, VAN DEN BRINK, MARCEL R M · 2015 to 2022
$5.2MDuke CTSA (Composite)KL2TR001115 · NCATS · DUKE UNIVERSITY · PI BOULWARE, LEIGH E, KRAFT, MONICA · 2013 to 2017
$5.1MRegulation of the intestinal stem cell compartment after hematopoietic transplantationR01HL125571 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI Alan M Hanash · 2015 to 2026
$4.4MMathematical ecology models of host-microbiota interaction in auto microbiota transplants (auto-FMT)R01AI137269 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI TAUR, YING, XAVIER, JOAO · 2019 to 2023
$3.8MNCATS NIH HHS KL2 TR001115NCI NIH HHS P01 CA023766NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA203950NCI NIH HHS R01 CA228308NCI NIH HHS R01 CA228358NHLBI NIH HHS K08 HL143189NHLBI NIH HHS R01 HL123340NHLBI NIH HHS R01 HL124112NHLBI NIH HHS R01 HL125571NIAID NIH HHS R01 AI032135NIAID NIH HHS R01 AI095706NIAID NIH HHS R01 AI137269NIAID NIH HHS R56 AI137269NIAID NIH HHS T32 AI100851NIAID NIH HHS U01 AI124275NIA NIH HHS P01 AG052359NIA NIH HHS P30 AG028716NIA NIH HHS R21 AG066388
Abstract
Disruption of intestinal microbial communities appears to underlie many human illnesses, but the mechanisms that promote this dysbiosis and its adverse consequences are poorly understood. In patients who received allogeneic hematopoietic cell transplantation (allo-HCT), we describe a high incidence of enterococcal expansion, which was associated with graft-versus-host disease (GVHD) and mortality. We found that
Indexed as
Gastrointestinal MicrobiomeHematopoietic Stem Cell TransplantationAgedAnimalsDysbiosisEnterococcusFecesFemaleGraft vs Host DiseaseHumansIntestinesLactoseMaleMiceMicrobiotaMiddle AgedLactoseRNA, Ribosomal, 16S
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.